搜索结果：timeline

A major challenge in Alzheimer's disease (AD) research is predicting who will develop AD, how it progresses, and how to slow, prevent, or reverse progression. Here, we apply a data-driven timeline inference framework to sparse longitudinal blood metabolomics data to reconstruct AD timelines and derive individual-specific timeline progression rates. Inferred temporal locations for each metabolomics sample along the AD timeline closely track clinical severity, while timeline progression rates capture inter-individual differences in the speed of pathophysiological progression. Genome-wide association studies of timeline progression rate identify novel loci distinct from those in AD case-control studies, notably showing no effect of the major risk locus APOE . These findings support a multidimensional paradigm of AD risk in which disease potential and progression act as partially independent factors. By explicitly modeling disease dynamics, this work reveals genetic contributions not captured by traditional approaches and provides a framework for studying AD and other progressive disorders.

One million deaths and seven million complications occur in an estimated 234 million procedures carried out worldwide each year; half of these deaths are preventable. Studies have reported a reduction in the mortality rate by 50% after the introduction of the WHO Surgical Safety Checklist (WHO-SSC). Surgical errors resulting from poor safety practices have had devastating outcomes; by identifying current practices and potential gaps in checklist adherence, this research aims to enhance patient safety and improve surgical outcomes. A retrospective, descriptive, cross-sectional study was performed at Upendra Devkota Memorial National Institute of Neurological and Allied Sciences to assess the compliance and completeness of the WHO-SSC in 50 consecutive patients undergoing cranial and spinal surgery under general anesthesia before and after COVID (Jan-Feb 2020 and 2023). The difference in compliance and completeness in elective and emergency cases, as well as in the two timelines, was also evaluated. In 2020, there were 19 emergencies and 31 electives; and in 2023, there were 16 emergencies and 34 electives. The WHO-SSC was not filled in 21% of emergency cases in 2020 and in 38% of emergency cases in 2023. In elective cases, around 25% of cases didn't have the WHO-SSC filled in both timelines. Regarding the completeness of the WHO-SSC, there was a stark difference noted in the elective and emergency cases in the Sign-In domain, with patient identity confirmation done in only 53% of cases and site marking in 20% of cases in emergency neurosurgery. WHO-SSC is a proven tool that helps reduce surgical errors, morbidity, and even mortality. If not regularly emphasized, the compliance with conducting WHO-SSC wanes over time, especially in emergency neurosurgery compared to elective procedures, which can result in devastating consequences.

Atopic dermatitis causes substantial symptom burden and impaired quality of life. Treat-to-target strategies can improve care by linking management decisions to explicit therapeutic goals, but Colombia lacks a consensus framework for routine practice. We conducted a modified Delphi consensus with 22 Colombian specialists in atopic dermatitis. Two anonymous voting rounds were informed by a systematic literature review. Governance safeguards, conflict-of-interest management, and sponsor noninvolvement were prespecified. Main targets and timelines were classified with a simplified evidence-level and recommendation-strength framework. The panel defined acceptable and optimal therapeutic targets using clinician-reported measures and patient-reported outcome measures. Eczema Area and Severity Index (EASI)-based thresholds and core symptom and quality-of-life instruments were supported by higher-quality evidence, whereas follow-up intervals, implementation strategies, and some adjunct measures relied more on expert consensus and contextual adaptation. The framework links response thresholds to reassessment timelines and treatment decisions for routine care. This consensus provides a practical treat-to-target framework for atopic dermatitis in Colombia and a model that may inform adaptation in other health systems.

To characterise the Early Hearing Detection and Intervention (EHDI) timeline and assess its relationship with psychological inflexibility among parents of children with hearing loss in Khorasan Razavi Province, Iran. Cross-sectional multicentre study. Multiple hearing rehabilitation centres in Mashhad, Iran. A total of 193 parents (71 fathers and 122 mothers) of children with documented congenital hearing loss.Intervention: not applicable (observational study). The primary outcomes were the child's age at diagnosis, age at intervention and the diagnosis-to-intervention interval. Parental psychological inflexibility was measured using the validated Persian version of the Acceptance and Action Questionnaire-Managing Child Hearing Loss (AAQ-MCHL). The mean age at diagnosis was 16.93±14.63 months and the mean age at intervention was 23.22±15.35 months, resulting in a mean diagnosis-to-intervention interval of 6.43±9.25 months. A weak but significant negative correlation was found between parental age and AAQ-MCHL score (r=-0.171, p=0.014). No significant correlations were found between AAQ-MCHL scores and any EHDI timeline variables (age at diagnosis, age at intervention or diagnosis-to-intervention interval; all p>0.05). Despite universal newborn hearing screening, substantial delays in diagnosis and intervention persist (16.9 and 23.2 months, respectively). Parental psychological inflexibility showed no meaningful association with service timing, suggesting that systemic, social and cultural barriers likely play the dominant role in EHDI delays.

Despite advances in breast cancer treatment, delays in care delivery remain a major challenge in many health systems, particularly in low- and middle-income countries. Evidence evaluating adherence to oncology quality metrics within public health systems remains limited. This study evaluated adherence to breast cancer treatment timeliness quality metrics in a Brazilian public referral hospital using established benchmarks (ASCO and ESMO) alongside Brazil's national 60-day treatment law and identified factors associated with delayed treatment initiation. This retrospective cohort study included women with stage I-III breast cancer treated at the Brazilian National Cancer Institute between 2016 and 2018. Adherence to six treatment timing quality metrics was evaluated, and multivariable logistic regression models were used to identify factors associated with delayed treatment initiation. A total of 966 patients were included. Only 35% of patients with hormone receptor-positive tumors initiated endocrine therapy within the recommended timeframe, and 23.6% of those undergoing breast-conserving surgery received radiotherapy within 365 days. In the ESMO-Q cohort, only 0.2% initiated chemotherapy within 120 days of diagnosis. Patients with Luminal A-like tumors were more likely to initiate treatment within recommended timeframes, whereas younger age and locally advanced disease were independently associated with treatment delays. Substantial delays in breast cancer treatment initiation were observed across all evaluated quality metrics within the Brazilian public health system, revealing a marked gap between recommended treatment timelines and real-world care delivery. Improving adherence to national and international quality benchmarks will require a better understanding of the patient- and system-level factors associated with treatment delays and the implementation of targeted interventions across the cancer care continuum. This retrospective cohort study evaluated adherence to international (ASCO, ESMO) and national quality metrics for breast cancer care in Brazil's public health system. Marked delays in treatment initiation were observed across endocrine therapy, radiotherapy, chemotherapy, and surgery, highlighting important gaps in timely cancer care delivery.

While delayed removal from play has been associated with worse outcomes following sport-related concussions (SRC), factors that predict delayed removal (vs. immediate) remain poorly understood. This study aimed to identify predictors of delayed removal following an SRC. A retrospective analysis included athletes aged 12-23 who presented to a regional sports concussion center within one day of injury. Patient demographics, injury characteristics, and clinical recovery metrics were extracted from medical records. Removal timeline was categorized as immediate (removed from play at time of injury) or delayed (continued participation). Comparisons across groups and a multivariable logistic regression model were conducted to identify predictors of delayed removal. In 291 athletes (29.6% female, median age = 15.6 [IQR = 14.5-16.8]), 109 (37.5%) had delayed removal (29.4% female; median age 15.7 [IQR 14.5-16.9]). Sex, race, sport, school, and competition type did not differ significantly between immediate and delayed removal groups. Athletes with loss of consciousness (LOC) had over 81% lower odds of delayed removal (OR = 0.19, 95%CI: 0.08-0.44; p < 0.01), and those evaluated on the field had 70% lower odds of delayed removal (OR = 0.30, 95%CI: 0.17-0.54; p < 0.01). Initial symptom scores were lower among those immediately removed (19.0 [IQR = 6.0-38.2]) compared to the delayed removal group (24.0 [IQR = 11.0-44.0]; p = 0.05). Return-to-learn, symptom resolution, and return-to-play timelines did not differ significantly between groups. On-field evaluations and observable clinical signs such as LOC strongly reduced risk of delayed removal from play after SRC. These findings emphasize the critical role of athletic trainers and prompt sideline recognition in reducing delayed removal and acute symptom burden.

Obesity injures the heart through hemodynamic, fibrotic, and adipokine pathways, but whether these reverse together or on different timelines after bariatric surgery is unknown. We performed, to our knowledge, the first integrated assessment of biventricular and biatrial cardiovascular magnetic resonance feature-tracking (CMR-FT), fibrosis and adipokine biomarkers, cardiovascular risk, and quality of life after laparoscopic sleeve gastrectomy (LSG), testing whether recovery is uniform or uneven. In this single-center prospective cohort, 40 patients underwent LSG; 8 were lost to follow-up, leaving 32 (28 with paired CMR; 26 women; aged 36.3&#x2009;&#xb1;&#x2009;7.6 years; baseline BMI 41.1&#x2009;&#xb1;&#x2009;4.8&#xa0;kg/m&#xb2;) studied before and a median 8.4 months after surgery. Left ventricular mass declined from 93.3 to 78.9&#xa0;g (p&#x2009;<&#x2009;0.001), alongside improved LVGLS (16.0 to 18.6%, p&#x2009;=&#x2009;0.003), MAPSE (p&#x2009;=&#x2009;0.004), and LVEF (p&#x2009;=&#x2009;0.021). RVEF increased (p&#x2009;=&#x2009;0.013) without parallel change in RVGLS or TAPSE. Left atrial volume index was unchanged, with only a reservoir-strain trend toward improvement (p&#x2009;=&#x2009;0.059). Only galectin-3 and endotrophin declined (both p&#x2009;<&#x2009;0.001); FABP4, apelin, and adiponectin were unchanged. NT-proBNP rose (p&#x2009;<&#x2009;0.001) despite falling blood pressure and improving strain. Metabolic risk factors improved broadly; Framingham risk and all SF-36 domains improved (p&#x2009;<&#x2009;0.001). Cardiac reverse remodeling after LSG is measurable but uneven within the first year. LV longitudinal mechanics improved alongside mass regression, whereas RVEF rose without parallel longitudinal change, consistent with afterload reduction rather than intrinsic RV recovery. Fibrosis-linked galectin-3 and endotrophin declined while adipokines remained static, indicating distinct fibrotic and adipokine timelines. The components that respond earliest are those that conventional preoperative assessment overlooks.

Timely initiation of outbreak research is essential for timely public health action. Yet conventional ethics review timelines, often measured in weeks, can delay study start-up and blunt the impact of interventions. During epidemics, routine review timelines of 2 weeks - 9 weeks delay research and weaken public health responses. Fast-tracking ethical review allows researchers to initiate studies at the height of an outbreak, when data are most relevant and informative. A spike in mpox cases across 20 Member States in 2024 prompted the Africa Centres for Disease Control and Prevention (Africa CDC) to declare its first Public Health Emergency of Continental Security. To expedite therapeutic trials, develop supporting policies, and mobilise resources for research and response, the Africa CDC and the World Health Organization (WHO) developed the Research and Innovation pillar within the Continental Incident Management Support Team (IMST). Among key research initiatives was a multicountry social and behavioural study led by Africa CDC. This article includes a synthesis based on implementation experiences from a multicountry mpox socio-behavioural study coordinated by the Africa CDC across 10 African countries. Within a month of IMST's inauguration, a master protocol and 10 country-specific protocols were finalised, led by Africa CDC in collaboration with national public health institutes and academic experts. Approval processes took 3 weeks - 11 weeks, with most countries completing review within 4 weeks - 8 weeks. This underscores the need to further streamline the ethical review process during emergencies and to improve efficiency. As the global research landscape continues to evolve, there is an urgent need for a unified continental ethical oversight framework to address the historical delays caused by multiple and overlapping requirements.

Cushing's syndrome (CS) requires prompt recognition and referral to explore definitive intervention. Delays can lead to increased mortality and death. This service evaluation aimed to distinguish time from initial referral to definitive surgical management in CS. Clinical standards for appropriate timelines for referral are undefined. A retrospective service evaluation across five specialised endocrine surgical centres reviewing the timeline from initial referral to definitive surgical treatment. All adult patients diagnosed with CS who underwent definitive surgery between January 2018 and December 2019. Data were collected on initial referrer, time to first clinical review, tests performed within non-surgical endocrinology centres, timing of referral to specialised endocrine surgical centre, clinical review (if applicable), multi-disciplinary meeting and definitive surgery. 71 patients received definitive surgical treatment for CS (37 pituitary CS and 34 adrenal CS). Median time from initial primary care referral to a specialised endocrine surgical centre was quicker if referred directly (56 days) than if initially referred to a non-surgical endocrinology hospital (159 days). The overall median time from all initial referrals to definitive surgical treatment was 211 days for pituitary CS and 253 days for adrenal CS. Patients referred directly to the specialised endocrine surgical centre had surgery in a median of 196 days (187 days and 252 days for pituitary and adrenal CS respectively) compared with 253 days in patients that were referred via a non-surgical endocrinology centre (249 days and 346 days for pituitary and adrenal CS respectively). There were delays from initial referral to definitive surgical treatment of CS. Clearer, clinically focussed pathways and (inter)national standards on early management of Cushing's syndrome should be considered to more address unwarranted delays in treating Cushing's syndrome.

Reactive lymphoid hyperplasia (RLH) is a common benign lesion, yet its occurrence at the eustachian tube orifice-a rare skull base site-is poorly reported. Lesions in this anatomical region are predominantly malignant, predisposing clinicians to misdiagnose benign lesions as nasopharyngeal carcinoma and lead to overexamination and therapy. We herein report a 58-year-old male patient presenting with persistent aural fullness and hearing loss caused by a lymphoproliferative mass at the right eustachian tube orifice. A clinical timeline is provided to clarify the disease course. The clinical characteristics, imaging features, endoscopic findings, surgical management, and pathological diagnosis are discussed. This case provides practical insights for the diagnosis and treatment of similar rare lesions, helping to reduce misdiagnosis and overtreatment.

To improve patient-centered dermatology care by identifying how patients prefer to approach medical decision-making and structuring their visit, using a brief 4-question intake survey focused on cognitive style. New patients at 2 dermatology clinics within the California Skin Institute completed a multiple-choice intake questionnaire before their first visit. The survey asked patients how many concerns they wanted to address, how much guidance they preferred in selecting treatment, whether they prioritized diagnosis or treatment during the visit, and their expected timeline for results. Associations between patient responses and demographics (sex, age, chief complaint) were analyzed using &#x3c7;2 tests. Among 257 patients (mean age: 38; 43% female), 96% of patients preferred to address only 1 or 2 concerns during their first visit; 75% preferred shared decision-making and 70% prioritized discussing treatment over their medical history. Patients bringing multiple concerns were significantly more likely to prefer autonomous decision-making (&#x3c7;2=24.0; P<0.001). Women more often preferred to discuss multiple concerns and to balance history with treatment (both P<0.01), while men leaned toward single-concern, treatment-focused visits. Single-center design and moderate sample size may limit generalizability. This brief, previsit framework offers a structured method to align dermatologic care with patients' cognitive and decision-making preferences-enhancing efficiency, rapport, and mutual understanding prior to the clinical encounter. By facilitating clearer communication from the outset, it may improve the quality of patient-centered care. Future studies will explore whether tailoring consultation styles to patient preferences can impact adherence, satisfaction, and clinical outcomes.

Epidemic trends respond dynamically to public health interventions, and retrospective evaluation of these responses is important for future preparedness. However, conventional epidemiological and time-series approaches often have limited ability to resolve the multi-scale and non-stationary fluctuations of epidemic data, which may obscure temporal structures associated with intervention timing. This study aimed to apply adaptive Fourier decomposition (AFD) to characterize coronavirus disease 2019 (COVID-19) epidemic dynamics and examine their temporal associations with public health policy interventions. Daily confirmed COVID-19 case data for Washington D.C. were collected through a multi-step source verification process using public data repositories and official local surveillance records. The archived New York Times COVID-19 GitHub repository was used as the initial structured dataset, and the Washington D.C. case series was cross-checked and corrected against the official District of Columbia government COVID-19 surveillance data. Public health intervention data were collected primarily from official mayoral orders and related policy announcements issued by the District of Columbia government. The epidemic time series and policy timeline were then aligned chronologically, and the Washington D.C. study period was divided into five epidemic waves. For comparative validation, the London daily COVID-19 case series was obtained from the authors of a published AFD-based study. AFD was applied to decompose the epidemic time series into interpretable time-frequency components, and newly constructed components were further generated for correlation analysis. The decomposition results were compared with those obtained using empirical mode decomposition (EMD) and variational mode decomposition (VMD). The third-order AFD components showed the strongest correlations with the original epidemic signal and effectively captured both long-term trend variation and short-term local fluctuations. In Washington D.C., the third-order components performed particularly well during the Omicron-dominated fifth wave, when major policy adjustments were implemented. Compared with EMD and VMD, AFD provided clearer multi-scale structures and stronger statistical associations with observed epidemic trajectories. Similar decomposition patterns and correlation results were observed in the London comparison, supporting the robustness of the proposed framework in a comparative urban setting. AFD provides a useful framework for analyzing non-stationary epidemic time series and for retrospectively examining temporal relationships between epidemic waves and public health interventions. In this study, the low-frequency and third-order AFD components captured the major epidemic trend more effectively than the comparison methods, suggesting that AFD may help identify meaningful shifts in epidemic structure under changing intervention conditions. These findings indicate that AFD may complement conventional epidemic surveillance by supporting interpretation of multi-scale epidemic fluctuations, improving assessment of intervention timing, and providing an additional analytical reference for future mitigation planning and monitoring of respiratory infectious disease outbreaks.

One of the key challenges in antibody engineering is the development of analytical screening methods to assess colloidal stability, ensuring that biologics are suitable for high-concentration formulation and administration. Charge-stabilized self-interaction nanoparticle spectroscopy (CS-SINS), a modified version of the conventional affinity-capture self-interaction nanoparticle spectroscopy (AC-SINS), has been adapted as a robust colloidal stability assessment&#xa0;for predicting high-concentration solution behavior. This method enables critical early-stage developability decisions by identifying colloidal stability issues before significant resources are invested, substantially reducing downstream attrition rates and accelerating candidate selection timelines. This study demonstrates that the assay seamlessly integrates into existing discovery workflows and can be performed in parallel with typical early-stage assays due to its minimal sample requirements, providing valuable data to predict high-concentration behavior without compromising other characterization efforts. It has been shown that routine dynamic light scattering (DLS) measurements, in addition to the shift in the plasmon resonance wavelength, can improve the reliability of the HTP method described here. Taken together, it is anticipated that the cross-validation using DLS measurements and automated analysis programs will facilitate the reliable selection of candidate antibody therapeutics of various modalities.

Influenza A virus (IAV) and influenza B virus (IBV) remain major global public health threats because of their rapid antigenic evolution and efficient human-to-human transmission. In contrast, influenza C virus (ICV) and influenza D virus (IDV) generally exhibit narrower host ranges and milder pathogenicity, yet their potential for interspecies transmission and zoonotic spillover still warrants attention. Conventional prevention strategies, such as inactivated and live-attenuated vaccines, suffer from prolonged development timelines and diminished efficacy against rapidly evolving viral strains. However, antiviral drugs are increasingly limited by the rapid emergence of drug-resistant variants. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) gene-editing technology has emerged as a promising platform for influenza prevention and control owing to its programmability and precise targeting capability. In this paper, we summarize recent advances in CRISPR-based strategies for influenza prevention and control. The RNA-targeting CRISPR-associated protein 13 (Cas13) system can recognize conserved viral RNA sequences and suppress replication across influenza subtypes, whereas the DNA-targeting CRISPR-associated protein 9 (Cas9) system can edit host susceptibility genes and thereby reduce cellular permissiveness to infection. In addition, lipid nanoparticle (LNP)-based delivery systems have become important tools for improving the in vivo delivery and expression of CRISPR components by enhancing targeting efficiency and reducing immunogenicity. CRISPR-based diagnostics, such as Specific High-sensitivity Enzymatic Reporter unLOCKing (SHERLOCK), further expand the clinical utility of this technology by enabling rapid and sensitive detection of influenza viruses. Despite these advances, substantial challenges remain, including delivery inefficiency, off-target activity, long-term safety concerns, and the risk of viral escape. With continued technological refinement and careful translational development, CRISPR may become a versatile tool for influenza prevention, diagnosis, and therapy.

Master athletes (&#x2265;40 years) represent a rapidly growing population with muscle injuries that differ substantially from those of younger athletes. Age-related changes, including type II fiber loss, fatty infiltration, fibrosis, tendon degeneration, and prior scarring, can significantly alter biomechanics, injury patterns, imaging appearance, and recovery timelines. This review summarizes epidemiology, key muscle groups, biomechanics, ultrasound and MR imaging features, and structured reporting considerations. Practical recommendations highlight prognostic factors, complications, and imaging strategies tailored to this unique population.

The peer-review and publication process can often seem opaque, especially to those outside of academia or settings in which research is a frequent occurrence. Those who may not have received training and mentorship on the peer-review and publication process could therefore be seen as being at a disadvantage when attempting to navigate those spaces. That lack of knowledge of the process could readily be seen as a barrier for those in less research-intensive settings, hindering their ability to submit their work for peer review. Accordingly, to alleviate such barriers, we provide a primer on the overall peer-review and publication process encountered in behavior analysis. This includes describing the process as a whole; types of decisions that could be rendered and received, and how to navigate each decision; how to select a journal to which to submit; timelines; and the roles of Associate Editors and reviewers in the process. We also describe several behavior-analytic journals most applicable to practitioners and the conditions under which they would (or would not) elect to submit to that journal. Moreover, and critically, we offer discourse on and clarify many common misconceptions surrounding the peer-review process (e.g., authors pay for publication).

Heterotopic ossification (HO) represents a highly active research field in pathological bone formation. Despite substantial advancements, a comprehensive understanding of its underlying mechanisms and clinical trajectory remains incomplete. A bibliometric and machine-learning latent Dirichlet allocation (LDA) analysis was performed using data retrieved from the Web of Science Core Collection database. A total of 4722 publications related to HO were identified. The most prolific countries included the USA, CHINA, GERMANY, the UK, JAPAN, SOUTH KOREA, ITALY, TURKEY, FRANCE, and CANADA . GERMANY demonstrated the highest citation strength, followed by CHINA . Aside from "heterotopic ossification," other frequently occurring author keywords included "fibrodysplasia ossificans progressive," "complications" and "total hip arthroplasty." In keywords plus, besides HO, replacement, bone-formation, and arthroplasty were the most frequently occurring terms. Institutional network analysis with subject-specific clustering indicated that Shanghai Jiao Tong University was significantly enriched in radiology, nuclear medicine and medical imaging, while Wilderness Spine Serv specialized in surgical management. A developmental timeline plot of a network of most contributing authors also was visualized, along with the most influential references. Meanwhile, citation analysis indicated that Kaplan FS and Shore EM were the top-cited authors. By LDA analysis, a total of 16 key topics were identified in this field with distinct period-proportion visualization. One of the topics, cell bone express differentiation and formation has clearly dominated the last 10 years. This study constitutes the most extensive text processing analysis of HO to date, offering valuable insights and directions for future development.

Background: MGMT-methylated glioblastomas respond well to temozolomide-based standard of care (Stupp protocol), demonstrate longer survival as compared to unmethylated tumors, and carry an increased risk of pseudo-progression. Establishing time to first true progression can serve as a non-invasive clinical reference point to distinguish true from pseudo-progression. Objective: To define the time to first true progression in patients with MGMT-methylated glioblastoma who were treated with the standard of care/Stupp protocol. Methods: We conducted a retrospective analysis from our institutional database of MGMT-methylated glioblastoma patients from 2018-2024. Time to first progression was measured from initial surgery to first true progression, as determined by a multidisciplinary team based on radiographic imaging review and/or pathology. Results: Fifteen patients met eligibility criteria. Median time to first progression of MGMT-methylated glioblastoma patients who received standard of care was twenty-one months. 40% of patients remained progression-free beyond thirty-six months after their initial surgery. Conclusions: Most patients with MGMT-methylated glioblastomas do not develop true progression within the first year and a half post-operatively. Therefore, MRI changes on surveillance scans should be carefully interpreted within this time frame. Expected timeline for true progression, alongside advanced radiographic imaging techniques and knowledge of treatment-specific pseudo-progression risk, may improve diagnostic accuracy.

Pharmaceutical manufacturing is changing rapidly as new therapeutic modalities, advanced manufacturing approaches, modern analytical tools, and novel drug-delivery technologies continue to emerge. While the scientific and technical potential of these innovations is clear, their adoption has often lagged due to regulatory challenges. Differences in regulatory expectations across regions, lengthy review timelines, and limited opportunities for coordinated engagement can slow or discourage the implementation of meaningful chemistry, manufacturing, and controls (CMC) advances. This review considers these barriers from an industry perspective, drawing attention to how cautious regulatory paradigms, fragmented guidance, and market-specific interpretations can reduce the incentive to introduce innovation, even when patient benefit is evident. Recent surveys, regulatory initiatives, and collaborative experiences suggest that progress is being made, particularly through innovation programs and reliance-based mechanisms; however, gaps remain in achieving consistent alignment and efficient lifecycle management. Looking ahead, greater use of cloud-based platforms to support real-time information sharing and collaborative regulatory review offers a practical path forward. Such approaches can improve transparency, reduce duplicate interactions, and encourage convergence without compromising regulatory rigor. By aligning regulatory practices more closely with scientific progress and the demands of today's advanced manufacturing, digital, and other 21st-century technologies, these collaborative models have the potential to accelerate innovation, support continuous improvement, and enable more timely global access to medicines.